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Inhibitors of viral entry are under consideration as topical microbicides to prevent HIV-1 sexual transmission. Small molecules targeting HIV-1
gp120 (BMS-378806) or CCR5 (CMPD167), and a peptide fusion inhibitor (C52L), each blocks vaginal infection of macaques by a SHIV. A
microbicide, however, must be active against multiple HIV-1 variants. We therefore tested BMS-C (a BMS-378806 derivative), CMPD167, C52L
and the CXCR4 ligand AMD3465, alone and in combination, against 25 primary R5, 12 X4 and 7 R5X4 isolates from subtypes A–G. At high
concentrations (0.1–1 μM), the replication of most R5 isolates in human donor lymphocytes was inhibited by >90%. At lower concentrations,
double and triple combinations were more effective than individual inhibitors. Similar results were obtained with X4 viruses when AMD3465 was
substituted for CMPD167. The R5X4 viruses were inhibited by combining AMD3465 with CMPD167, or by the coreceptor-independent
compounds. Thus, combining entry inhibitors may improve microbicide effectiveness.
© 2007 Published by Elsevier Inc.Keywords: HIV-1; Microbicide; Clades; Entry inhibitors; R5 X4 tropismIntroduction
In the continuing absence of an effective vaccine, the use of a
topical microbicide represents a credible alternative method to
reduce the sexual transmission of human immunodeficiency
virus type 1 (HIV-1). The microbicide concept remains to be
validated, in that no compounds have yet been shown to prevent
HIV-1 transmission in efficacy trials (Dhawan and Mayer, 2006;
Klasse et al., 2006; Lee et al., 2003; Shattock and Moore, 2003).
Several efficacy trials of early generation microbicide candi-
dates, mostly polyanion-based, are due to be completed in the
next few years. Provided these microbicides are used regularly,
it is possible that one or more of them will show significant
efficacy, although trials of one polyanion, cellulose sulphate,⁎ Corresponding author.
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0042-6822/$ - see front matter © 2007 Published by Elsevier Inc.
doi:10.1016/j.virol.2007.03.001were recently abandoned due to an increased rate of infections
in the active arm. If the other polyanions are also found not to be
protective, the focus will fall on the next generation of
microbicide candidates that are in pre-clinical development or
early-stage clinical trials (Dhawan and Mayer, 2006; Klasse et
al., 2006; Lederman et al., 2006; Shattock and Moore, 2003).
Among such next-generation concepts are entry inhibitors,
compounds that inhibit the fusion of HIV-1 with its target cells
by specifically interfering with virus–receptor interactions or
the subsequent stages of the entry process. Several different
entry inhibitors have now been shown to be effective at pre-
venting SHIV infection of macaques by the vaginal and/or
rectal routes (Dhawan and Mayer, 2006; Klasse et al., 2006;
Lederman et al., 2006). One significant problem that will need
to be overcome by an entry-inhibitor-based microbicide,
indeed by any microbicide, is the global sequence diversity
of HIV-1 (McCutchan, 2006; Walker and Korber, 2001). As is
now well appreciated, HIV-1 is an extraordinarily variable
virus, its diversity exceeding other viral pathogens' by orders
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of HIV-1 vaccines, and it is just as relevant an issue for
microbicide development; any product that could prevent the
transmission of only a small subset of the viruses its users
encountered would not be of much practical value.
The breadth of protection against diverse HIV-1 strains
cannot be readily gauged in the macaque model, because only a
very few SHIVs are available for microbicide testing (Klasse et
al., 2006; Lederman et al., 2006). Tissue-culture studies must,
therefore, suffice. It is possible to assess the breadth of reactivity
of vaccine-induced antibodies or neutralizing monoclonal
antibodies (MAbs) in vitro by measuring their ability to inhibit
the infection of target cells by viruses from multiple different
genetic subtypes (Binley et al., 2004; Brown et al., 2005; Burton
et al., 2004; Li et al., 2005; Moore and Burton, 2004). A
neutralizing antibody is, of course, an entry inhibitor, one that
works by binding to the viral envelope glycoproteins (Burton et
al., 2000; Klasse and Sattentau, 2002). Hence the same or
similar virus test panels used for neutralization studies can be
used to gauge the breadth of activity of candidate microbicides
in vitro.
We have, therefore, assembled a multi-subtype HIV-1 test
panel and used it to study a selection of different entry
inhibitors, including compounds we have previously shown to
be effective at preventing SHIV infection of macaques after
vaginal challenge (Veazey et al., 2005). The test compounds are
the small-molecule CCR5 inhibitor CMPD167, the gp120-
binding attachment inhibitor BMS-C, the gp41-targeted fusion
inhibitory peptide C52L, and the small-molecule CXCR4
inhibitor AMD3465. We have tested each of these inhibitors
as individual agents, and we have also evaluated their per-
formance in pair-wise and triple combinations. The rationale for
testing inhibitor combinations is that the use of several
compounds with different, complementary mechanisms of
action is one possible answer to the problems posed by HIV-1
diversity (Veazey et al., 2005). The chances of a virus being
simultaneously resistant to three compounds is obviously less
than to any single inhibitor, a principle well established from
clinical experience with drug-based therapies for HIV-1
infection (Yeni et al., 2004). Furthermore, the combination of
CXCR4- and CCR5-specific inhibitors may be useful for
countering the transmission of dual-tropic viruses since,
although X4 viruses are rarely transmitted, this can occur
(Dhawan and Mayer, 2006; Gupta and Klasse, 2006; Klasse
et al., 2006; Margolis and Shattock, 2006; Moore et al., 2004).
Results
Entry inhibitor microbicide candidates and virus test panels
We have previously shown that the small-molecule CCR5
inhibitor CMPD167, the gp120-binding small-molecule attach-
ment inhibitor BMS-378806 and the gp41–peptide fusion
inhibitor C52L, alone and in combination, can protect rhesus
macaques against infection by the R5 virus SHIV-162P3 when
used as vaginal microbicides (Veazey et al., 2005). BMS-C is a
member of the same structural family of compounds as BMS-378806 but has greater potency in vitro, so we selected it for
further study. AMD3465 is a small-molecule inhibitor that
binds to CXCR4 (Hatse et al., 2005). We are now evaluating it
in the macaque model for protection against the vaginal
transmission of viruses that use CXCR4 for entry into primary
cells in vitro.
In the present study, we have explored the activities of each
of these compounds against HIV-1 primary isolates from
different genetic subtypes in vitro, to gain insights into their
practical utility as topical microbicides. Based on the known
properties of these inhibitors, CMPD167 should only be active
against R5 viruses and AMD3465 only against X4 viruses,
whereas the inhibitory effects of BMS-C and C52L should be
coreceptor-independent (Guo et al., 2003; Matthews et al.,
2004). Some of the test viruses were derived from a test panel
put together for evaluating the breadth of activity of vaccine-
induced neutralizing antibodies (Brown et al., 2005). Others
were isolated from individuals in the relatively early stages of
infection, so might be representative of viruses that expand in
the new host post-transmission (Rusert et al., 2005).
The test viruses were grouped by coreceptor usage: R5, X4
or dual-tropic (R5+X4 or R5X4). In total, we used 25 R5
viruses, 12 X4 viruses and 7 dual-tropic viruses, from 7 genetic
subtypes or circulating recombinant forms (CRFs) (Table 1).
We placed more emphasis on the R5 virus test panel because
viruses with this phenotype are the most commonly transmitted
successfully (Lederman et al., 2006; Moore et al., 2004).
However, although X4 viruses are rarely transmitted, it is
possible that a microbicide might have to counter viruses of this
phenotype, particularly if the transmitter has been infected for
several years, allowing the evolution of CXCR4-using strains
(Dhawan and Mayer, 2006; Gupta and Klasse, 2006; Klasse et
al., 2006; Margolis and Shattock, 2006; Moore et al., 2004).
Isolates that use only CXCR4 are rare compared to ones that
contain mixtures of viruses with either phenotype (R5+X4)
and/or clonal viruses that can use both coreceptors (R5X4)
(Brumme et al., 2005; Moyle et al., 2005). A caveat is that the
most commonly used assays for viral phenotype are based on
cell lines such as U87/CD4-CCR5 and U87/CD4-CXCR4
(Brumme et al., 2005; Moyle et al., 2005), and coreceptor usage
patterns on cell lines and on primary cells are not always
correlated (Yi et al., 2005; Zhang and Moore, 1999; Zhang et
al., 1998). We therefore tested the entry inhibitors only against
dual-tropic isolates that we had confirmed could use both CCR5
and CXCR4 to enter primary CD4+ T-cells, by showing that
they were sensitive to a combination of the CCR5-specific
inhibitor CMPD167 with a CXCR4-specific inhibitor
(AMD3465 or AMD3100) (Zhang and Moore, 1999; Zhang
et al., 1998) (and data not shown). These isolates probably
contain mixtures of R5 and X4 viruses and, perhaps, also
genuinely dual-tropic viruses able to use either coreceptor.
Evaluation of entry inhibitors, alone and in combination,
against primary isolates from multiple genetic subtypes
Each inhibitor was initially tested against each virus in a
PBMC-based replication assay at four different concentrations
Table 1
Coreceptor usage, genetic subtype, source and p24 production in PBMC for the
HIV-1 test isolates
Isolate Coreceptor
usage
Subtype Source reference HIV-1 p24 a
(ng/ml)
KNH 1088 R5 A Polonis, V 6.6
KNH 1144 R5 A Polonis, V 5.0
KNH 1207 R5 A Polonis, V 3.9
JRFL R5 B NIH 6.5
AK103 R5 B Trkola, A 8.0
AK115 R5 B Trkola, A 3.8
56313 R5 C Polonis, V 6.2
94ZW109 R5 C JPM (Trkola 97) 24
PBL288(411) R5 C Polonis, V 19
DJ259 R5 C JPM (Trkola 97) 15
TZBD 9/11 R5 C Polonis, V 10
A08083M1 R5 D Polonis, V 11
J32228M4 R5 D Polonis, V 2.7
NKU 3006 R5 D Polonis, V 6.7
A07412M1 R5 D Polonis V 2.4
BZ162 R5 F JPM (Trkola 97) 12
MSD28019 R5 F Trkola A 12
R1 R5 F JPM (Trkola 97) 5.7
G3 R5 G Abimiku,
A (via NIH)
12
AK112 R5 G Trkola, A 23
MSD28017 R5 G Trkola A 16
RU570 R5 G Bobkov, A and
Weber, J (via NIH)
17
AK104 R5 CRF01_AE Trkola, A 9.6
002(PIS2 CD4) R5 CRF01_AE Trkola, A 3.0
CM235 R5 CRF01_AE JPM (Trkola 97) 16
HC4 X4 B JPM (Trkola 97) 28
2044 X4 B JPM (Simmons 96) 36
MN X4 B NIH 14
ZAM-20 X4 C JPM (Trkola 97) 21
SW7 X4 C Morris 25
UG270 X4 D JPM (Trkola 97) 26
92UG046 X4 D NIH 24
92UG024 X4 D NIH 26
93UG070 X4 D NIH 22
94TH304 X4 CRF01_AE JPM (Zhang 96) 38
93TH053 X4 CRF01_AE NIH 12
E4002
(90CF402)
X4 CRF01_AE Gao, F 16
92RW009 R5X4 A NIH 62
92US076 R5X4 B Sullivan,
J (via NIH)
68
2076 Cl 3 R5X4 B JPM (Trkola 97) 46
CC 2/86 R5X4 B Connor, R 18
DH123 R5X4 B JPM (Trkola 97) 27
SP116 R5X4 B Trkola, A 23
S2206 R5X4 B Trkola, A 19
a The concentrations represent the total p24 (intracellular and extracellular)
content per culture volume on Day 7 (or 10 or 14) of cultures of PBMC from 3 to
4 different donors. The values are means of 3 intra-experimental replicates and
are rounded off to two significant digits.
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to gain an insight into how sensitive each virus was without
determining formal IC50 values, which would be logistically
infeasible given the number of viruses and inhibitors involved
in the study. We selected 90% inhibition of p24 production as a
marker for definitive, high-level activity of a compoundagainst a test virus (see Methods). At the highest tested
concentration, 1 μM, C52L inhibited all viruses by >90%
(Table 2). This degree of potency is compatible with its
reported range of IC90 values, 20–200 nM, against eight
viruses (Deng et al., 2007), six of which were re-tested here,
and also with its reported IC50 values against HIV-1BaL and
SHIV-162P3 (Veazey et al., 2005). BMS-C at 1 μM inhibited
all the R5X4 viruses by >90%, but only 84% of the R5 and
58% of the X4 viruses. A 1 nM concentration of CMPD167
was sufficient to inhibit all the R5 viruses by >90%, while a
5 μM concentration of AMD3465 was required for a similar
degree of inhibition of all the X4 viruses (at this concentration,
some non-specific effects of AMD3465 became apparent).
Thus single inhibitors showed substantial breadth of activity
against the current panel of viruses, albeit at different con-
centration ranges.
We then sought to identify the concentration of each
inhibitor that would be active at this level (>90% inhibition)
against a substantial subset (∼50%) of the test viruses, so that
we could assess whether combining different inhibitors
increased the breadth of coverage against the test panel as a
whole. Our intention was not to determine whether different
inhibitors could act additively or synergistically; to do that
would require complex titrations of each inhibitor, alone and
in pairs, against each virus, which is not practical in a study on
this scale (a more narrowly focused study of synergy is now in
progress). Instead, we tried to ascertain whether any viruses
would be resistant to intermediate concentrations of two or
more inhibitors. Obviously, the use of any one inhibitor at a
concentration that was, itself, sufficient to inhibit almost all
the test viruses would not allow us to determine whether
adding a second inhibitor could now suppress the remaining
viruses. Ideally, the hit-rate for each individual compound
across the entire test panel would be ∼20–50% at the most
suitable concentration, but given the diversity of the viruses in
the test panel, and virus-dependent variation in inhibitor
potency, it was not always possible to achieve this goal (Figs.
1–3; Table 2).
When tested at low, sub-optimal concentrations, each of
CMPD167 (0.1 nM), BMS-C (1 nM) and C52L (1 nM)
inhibited only a subset (0–16%) of the 25 R5 viruses by 90%,
but the breadth of coverage was increased by the use of two or
three inhibitors together (Table 2A). For example, CMPD167
alone inhibited only 8% of the viruses at this low concentra-
tion, BMS-C only 16%, but the two together were active
against 56% of the panel. By itself, at the 1 nM concentration,
C52L inhibited none of the test viruses by 90%, but its
presence increased the breadth of coverage conferred by either
CMPD167 or BMS-C, and the triple inhibitor combination
was active against 68% of the viruses in the panel (Table 2A).
When the concentration of each individual inhibitor was
increased by 10-fold, CMPD167 (1 nM) now inhibited 100%
of the test viruses, demonstrating its substantial breadth of
activity against R5 viruses, but preventing any assessment of
the effect of combining it with other inhibitors. However, the
combination of BMS-C (10 nM) with C52L (10 nM) was
more broadly active than either inhibitor was by itself (80%
Table 2
The relative frequency with which various inhibitors inhibit p24 production by >90% among the test isolates
(A) R5 viruses (n=25)
Concentration CMPD167
(%)
BMS-C
(%)
C52L
(%)
CMPD+BMS-C
(%)
CMPD+C52L
(%)
BMS+C52L
(%)
Triple combination
(%)
Lowa 8 16 0 56 24 36 68
High b 100 68 4 100 100 80 100
Top c 100 84 100 100 100 100 100
(B) X4 viruses (n=12)
Concentration AMD3465
(%)
BMS-C
(%)
C52L
(%)
AMD+BMS-C
(%)
AMD+C52L
(%)
BMS+C52L
(%)
Triple combination
(%)
Lowd 17 17 0 58 8 17 50
High e 75 50 8 83 92 75 92
Top f 100 58 100 100 100 100 100
(C) R5X4 viruses (n=7)
Concentration AMD3465
(%)
CMPD167
(%)
AMD+CMPD
(%)
BMS-C
(%)
C52L
(%)
CoR+BMS
(%)
CoR+C52L
(%)
BMS+C52L
(%)
Quadruple
combination (%)
Lowg 0 0 0 14 0 29 0 14 29
High h 14 14 100 86 0 100 100 86 100
Top i 71 14 100 100 100 100 100 100 100
CoR=mixture of AMD3465 with CMPD167.
a 0.1 nM for CMPD167 and 1 nM for all others, alone and in combinations.
b 1 nM for CMPD167 and 10 nM for all others, alone and in combinations.
c 100 nM for CMPD167 and 1 μM for all others, alone and in combinations.
d 5 nM for AMD3465 and 1 nM for all others, alone and in combinations.
e 50 nM for AMD3465 and 10 nM for all others, alone and in combinations.
f 5 μM for AMD3465 and 1 μM for all others, alone and in combinations. At this high concentration of AMD3465, non-specific effects on some R5 virus
infections were also seen.
g 5 nM for AMD3465, 0.1 nM for CMPD167, and 1 nM for all others, alone and in combinations.
h 50 nM for AMD3465, 1 nM for CMPD167, and 10 nM for all others, alone and in combinations.
i 5 μM for AMD3465, 100 nM for CMPD167, and 1 μM for all others, alone and in combinations. At this high concentration of AMD3465 non-specific effects on
R5 virus infection were also seen.
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added alone; Table 2A).
A similar finding was made with the X4 virus test panel.
Thus, AMD3465 (5 nM) inhibited 17% of the viruses and BMS-
C (1 nM) also inhibited 17%, but 58% of the viruses were
sensitive to the two compounds added together. The addition of
C52L (1 nM) did not increase the frequency of inhibition (the
marginal decreases were insignificant; Fisher's exact test,
P>0.5). At higher concentrations (50 nM AMD3465, 10 nM
BMS-C and 10 nM C52L), the individual compounds inhibited
part of the test panel (8–75%), but the breadth of coverage was
again improved by the use of combinations (75–92% inhibition;
Table 2B). When dual-tropic viruses were tested, the benefits of
inhibitor combinations were again sometimes observable; for
example, at the higher concentration of 50 nM AMD3465 and
1 nM CMPD167, each compound alone inhibited only 14% of
the viruses, whereas the combination was active against 100%
(Table 2C). This is an expected finding in a multi-cycle
replication assay: any dual-tropic virus that can use a coreceptor
that is not blocked will be able to amplify during the course of
the culture, overcoming any partial inhibition caused by
blockade of the other coreceptor.
The method of data presentation used in Table 2 means that 0
to 90% inhibition of a test virus by an inhibitor would be classedas negative. When the extent of inhibition is <50%, such a
categorization is probably reasonable, given the well-known
limitations of the PBMC-based replication assay and its lack of
precision in this range of inhibition. However, 85% inhibition,
for example, does not necessarily indicate a lack of activity of a
test compound against a test virus. We therefore analyzed the
data sets in a different way, by calculating the mean degree of
inhibition achieved by each concentration of each inhibitor and
inhibitor-combination against all the isolates in each test panel
(Figs. 1–3). The error bars in these figures represent the
standard deviation and illustrate the extensive biological
variation among the isolates, not the degree of experimental
error within the PBMC assay. Using more than one compound
clearly increased the degree of inhibition of the R5 viruses in the
test panel, more so when the inhibitor concentrations were low
(Fig. 1A) than when they were 10-fold higher (Fig. 1B). Similar
results were observed in the experiments using the X4 virus test
panel, particularly at the higher inhibitor concentrations (Fig.
2B). At low, sub-optimal concentrations, none of the individual
inhibitors was very effective against the R5X4 virus test panel,
not even the tropism-independent compounds BMS-C and
C52L. Combining AMD3465 with CMPD167 gave only∼30%
inhibition at these low concentrations, and combining BMS-C
with C52L provided ∼40% inhibition. The combination of
Fig. 2. The bars represent the extent of inhibition of p24 production in the
PBMC infectivity assay caused by the individual compounds or combinations
listed on the category axis. The average degrees of inhibition for 12 X4 viruses
are shown, with error bars indicating the S.D. The three inhibitors were used at
the following concentrations, alone or in combination: (A) AMD3465, 5 nM;
BMS-C, 1 nM; C52L, 1 nM. (B) AMD3465, 50 nM; BMS-C, 10 nM; C52L,
10 nM.
Fig. 1. The bars represent the extent of inhibition of p24 production in the
PBMC infectivity assay caused by the individual compounds or combinations
listed on the category axis. The average degrees of inhibition for 25 R5 viruses
are shown, with error bars indicating the S.D. The three inhibitors were used at
the following concentrations, alone or in combination: (A) CMPD167, 0.1 nM;
BMS-C, 1 nM; C52L, 1 nM. (B) CMPD167, 1 nM; BMS-C, 10 nM; C52L,
10 nM.
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together) did, however, improve the average inhibition to 55–
60% (Fig. 3A). Clear benefits of inhibitor combinations were
apparent when the various compounds were tested against the
R5X4 viruses at the 10-fold higher concentrations (Fig. 3B). It
should be noted that at higher, but still rather low, concentra-
tions (50 nM and 1 nM), the combination of AMD3465 with
CMPD167 was sufficient to completely inhibit infection by all
the R5X4 viruses (Fig. 3B and Table 2C).
Pan-resistance and causes of weak inhibition
To assess whether there was any tendency to pan-resistance
among the isolates, i.e. whether any isolates were insensitive to
more than one inhibitor, we correlated the degree of inhibition
caused by fixed concentrations of the individual compounds.
These pair-wise correlations of single inhibitors against eachother were always poor, r2<0.16, which indicates that pan-
resistance is rare among these test isolates for these inhibitors.
We also addressed whether the amount of viral replication
could affect the extent to which the different viral stocks were
susceptible to inhibition. We observed no such correlations for
BMS-C, C52L or the coreceptor ligands within the whole set of
isolates (r2<0.25). We did, however, as an exception, observe a
negative correlation between viral growth and AMD3465
inhibition in the X4 group (r2 =0.63, P=0.0058). Hence
differences in the extent of inhibition were for the most part
not influenced by variations in the infectious viral dose used to
initiate the replication assays for the different test viruses.
Finally, we addressed whether there was any difference in the
sensitivity of the different isolates to the various inhibitors that
was specific to any individual genetic subtype. First, we
grouped the 44 R5, R5X4 and X4 isolates by subtypes. The
degrees of inhibition by the coreceptor-independent inhibitors
Fig. 3. The bars represent the extent of inhibition of p24 production in the
PBMC infectivity assay caused by the individual compounds or combinations
listed on the category axis. The average degrees of inhibition for 7 R5X4 viruses
are shown, with error bars indicating the S.D. The four inhibitors were used at
the following concentrations, alone or in combination: (A) AMD3465, 5 nM;
CMPD167, 0.1 nM; BMS-C, 1 nM; C52L, 1 nM. (B) AMD3465, 50 nM;
CMPD167, 1 nM; BMS-C, 10 nM; C52L, 10 nM.
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compared. The degrees of inhibition among the different
subtypes caused by CMPD167 (0.1 nM), in dual and triple
combination with BMS-C and C52L (both at 1 nM), were then
compared for the 25 R5 isolates. A Kruskal–Wallis test did not
indicate that the median degrees of inhibition within the
subtypes differed significantly in either case (P>0.05). Hence,
we conclude that the genetic subtype is not a strong determinant
of sensitivity to the entry inhibitors we have studied here.
Discussion
HIV-1 global diversity is just as serious an issue in the
development of an effective microbicide as it is for a vaccine.
Clearly, a microbicide would be of limited value if it were only
active against a small subset of the HIV-1 strains present in thegeographic area where it was being used. In addition, adjusting
the formulation of a microbicide to take account of the virus
strains prevalent in different parts of the world (i.e., developing
subtype-specific microbicides) would be undesirable, to say the
least. Here, we have conducted an in vitro study of the activity
of selected entry inhibitor microbicide candidates against HIV-1
isolates from different genetic subtypes. Our intent was to
obtain baseline information on the extent to which HIV-1
sequence diversity could affect the performance of entry
inhibitor-based microbicides, at least in vitro, and whether
combinations could be useful in this regard. The particular
inhibitors we chose are the ones we have studied, or are
presently studying, in the macaque model, to determine their
efficacy against vaginal challenge with SHIVs (Veazey et al.,
2005; Veazey et al., unpublished results). CMPD167 and BMS-
C are presently being evaluated as clinical candidates by the
International Partnership for Microbicides.
We report here that the activity of each of the selected
inhibitors is substantially subtype-independent. In particular,
the small-molecule CCR5 inhibitor CMPD167 and C52L, a
gp41 peptide inhibitor of fusion, were almost pan-reactive
against R5 viruses, and C52L was also active against X4 strains.
CMPD167 was, as expected, inactive against X4 isolates.
Conversely, the CXCR4 inhibitor AMD3465 was pan-reactive
against X4 viruses, but inactive against R5 viruses. The gp120-
binding attachment inhibitor BMS-C was effective against most
R5 and X4 viruses, although some were insensitive. Hence
viewed solely from the perspective of their breadth of activity,
these compounds are all suitable candidates for development as
a microbicide component(s). Other factors, of course, will
eventually determine whether any or all of them fulfill all the
criteria necessary to create a useful product, including safety
and the cost and practicality of manufacture and formulation
(Klasse et al., 2006).
We were not able to include enough test viruses from each of
the major genetic subtypes to determine whether any particular
subtype is more or less sensitive than average to the entry
inhibitors. However, within the limitations of the panel size,
there was no indication of any substantive, subtype-specific
pattern to the actions of any of the compounds, which is
consistent with earlier reports on other entry inhibitors (Cilliers
et al., 2003; Trkola et al., 1998, 2001) and with the subtype-
independent nature of the HIV-1 fusion process (Gallo et al.,
2003; Pope et al., 1997). For entry inhibitors in general, any
subtype-specific effects may be fairly subtle, at most. Likewise,
the microbicide candidate CAP (cellulose acetate 1,2-benzene
dicarboxylate), which interacts with positively charged residues
in the Env glycoprotein, is active against viruses from multiple
subtypes (Lu et al., 2006).
There are obvious advantages to using several different
inhibitors of HIV-1 entry in a combination microbicide, for
essentially the same reason that a cocktail of inhibitors and not
monotherapy is used to treat HIV-1 infection (Yeni et al., 2004).
In the context of the present study, one reason to use an inhibitor
combination is that viruses resistant to one compound may still
be sensitive to others. For example, 16% of the R5 test viruses
were insensitive to BMS-C (<90% inhibition at 1 μM), but all
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and/or C52L. No virus from among the 44 tested was
insensitive to two of the different categories of inhibitor at the
highest concentrations (0.1–5 μM excluding, of course, the
expected ineffectiveness of the CCR5 inhibitor against X4
viruses and the CXCR4 inhibitor against R5 viruses). Thus in a
combination of CMPD167, C52L and BMS-C, at least two of
the inhibitors, and usually all three, were active against the R5
viruses in the test panel. Moreover, combining a CCR5 inhibitor
with a CXCR4 inhibitor, or with coreceptor-independent
inhibitors, is one solution to the problem of the rare
transmissions of CXCR4-using viruses (Dhawan and Mayer,
2006; Lederman et al., 2006; Margolis and Shattock, 2006;
Moore et al., 2004).
All of the above conclusions are, of course, conditional on
the concentrations of the test compounds, because their
activities are dose-dependent and we used different concentra-
tions in the nM to μM range in various experiments. In the
macaque model, the inhibitors are applied at much higher, mM,
concentrations when they provide protection against vaginal
challenge with SHIV-162P3 (Veazey et al., 2005). Although the
local inhibitor concentrations at the site of virus deposition are
not known, it seems unlikely that they will be as low as the nM
range, at least initially (Klasse et al., 2006). The local
concentrations will dissipate with time, so eventually the
lower, less active range will be reached. What inhibitor
concentrations must be present within the vagina to protect
women, and for how long, are not yet known, of course.
A second advantage of the use of inhibitor combinations is
the potential for synergy; that is, the mutually reinforcing
activity of two different compounds with complementary
mechanisms of action. We did not, in this study, perform
formal synergy analyses, but we have previously reported
synergy between CMPD167 and both C52L and BMS-378806
against SHIV-162P3 replication in vitro (Veazey et al., 2005).
There are also several other reports of synergy between CCR5
inhibitors similar to CMPD167 and gp41 peptide fusion
inhibitors similar to C52L (Tremblay et al., 2002,
2005a,2005b). In the context of a microbicide formulation for
human use, synergy would act to reduce the amount of each
inhibitor required to provide an effective blockade to HIV-1
transmission, a useful bonus to combination-based strategies.
There are two obvious limitations to this study: the choices
of the test viruses and the target cells used in the infection
inhibition assay. The viruses were almost all isolated from the
peripheral blood of HIV-1-infected people, some relatively
early in infection, others several years later. How precisely such
viruses mimic those present in genital fluids that a microbicide
must block from establishing a new infection remains to be
determined, because such viruses are unavailable (Klasse et al.,
2006). The same considerations apply, of course, to the design
of virus test panels for the evaluation of MAb-based HIV-1
vaccines (Binley et al., 2004; Brown et al., 2005; Li et al., 2005;
Mascola et al., 2005; Rusert et al., 2005). One possible
approach is to use viruses isolated relatively early after HIV-1
infection of a new host, and we included such examples in our
R5 test panel. However, viruses that expand in the host maydiffer phenotypically from those present in semen or vaginal
fluids (Klasse et al., 2006). Until test panels are assembled that
include the latter categories of HIV-1 variants, it cannot be
determined whether this issue is truly relevant. We suspect,
however, that any such influence on microbicide efficacy in
vitro will not be substantive enough to alter the broad
conclusions we have drawn here.
The second principal limitation to this study is our use of
PBMC as the target cell for HIV-1 replication. Given the scale
of the study (44 test viruses and 4 inhibitors, alone and in
combination) we had little choice but to work with PBMC.
However, these cells are not the immediate target cells for
sexual transmission of HIV-1 (Gupta and Klasse, 2006; Haase,
2005; Miller et al., 2005). Thus, in principle, using PBMC could
affect our conclusions, but again probably only to a minor
extent. Firstly, several of the same compounds we have shown
to be active against HIV-1 infection of PBMC also inhibit
SHIV-162P3 vaginal transmission to macaques, so they must be
active against whatever cells are infected early in the infection
process (Veazey et al., 2005). Secondly, the principal cell type in
which HIV-1 replicates in activated PBMC is the CD4+ T-cell.
Such cells are present at early sites of virus replication after
vaginal transmission of SIVs or SHIVs, as are others such as the
macrophage and dendritic cell (Gupta and Klasse, 2006; Haase,
2005; Hladik et al., 2007; Miller et al., 2005). Small-molecule
CCR5 inhibitors and gp41-based fusion peptides have pre-
viously been shown to inhibit HIV-1 infection of both these cell
types in vitro, so we would not expect too much difference from
our present results if we had used other cell types (Ketas et al.,
2003a,2003b; Willey et al., 2005). In broad terms, the
mechanism of HIV-1 entry, and hence of its inhibition, is
independent of the target cell in vitro (Gallo et al., 2003).
Nonetheless, it will be essential to also perform the present type
of study using other in vitro experimental systems, such as
cervical tissue explants and dendritic cells, to see whether any
issues arise that are not visible in studies that use PBMC.
Whether any in vitro system can always predict the activity of
an inhibitor against virus transmission in vivo, in a model
system or the real world, of course remains to be determined.
Using more than one entry inhibitor might also reduce the
development of resistance (Olson and Maddon, 2003). Most
women in the developing world are unaware of their HIV-1
status, so it is probable that, outside a clinical trial setting,
microbicides would be used by infected women. It is unclear
whether any topical agent will cause resistant variants to evolve
systemically, but inhibitor absorption into the body could result
in sub-therapeutic levels that select for resistance, perhaps at
local sites close to where the inhibitor is applied. This concern
may apply to conventional antiviral drugs that are now being
used widely for treating HIV-1 infection, something that does
not yet apply to entry inhibitors. There is an argument that, in
high-incidence areas like sub-Saharan Africa, entry inhibitors
might best be reserved for the prevention of HIV-1 transmission,
to avoid any possible impact of resistance development on the
efficacy of therapy.
Overall, our results support the development of microbicide
formulations based on the use of several different inhibitors of
438 T.J. Ketas et al. / Virology 364 (2007) 431–440HIV-1 attachment and entry. If such a microbicide can be
developed successfully, its efficacy may not be influenced too
drastically by subtype-dependent HIV-1 sequence variation. We
do not seek to trivialize the problem of HIV-1 sequence
diversity, which is and will always remain formidable
(McCutchan, 2006; Walker and Korber, 2001). However,
carefully chosen entry inhibitors, if used in combination, may
be effective at blocking HIV-1 transmission irrespective of the
viral subtype.
Methods
Entry inhibitors and MAbs
The small-molecule CCR5 inhibitor CMPD167 and the
gp41-peptide fusion inhibitor C52L have been described
previously, including evaluations of their activity against
SHIV transmission to the rhesus macaque after vaginal admi-
nistration (Veazey et al., 2005; Deng et al., 2007). BMS-C is a
more potent member of the same structural family of
compounds as the gp120-binding attachment inhibitor BMS-
378806 (Guo et al., 2003). AMD3465 is a small-molecule
inhibitor that binds to CXCR4 (Hatse et al., 2005).
HIV-1 isolates
The isolates of defined coreceptor usage (R5, X4, R5X4) and
genetic subtypes used in this study have all been described
previously (see Table 1).
Preparation of PBMC and use in HIV-1 infection assay
Peripheral blood mononuclear cells (PBMC) were prepared
from leukopacks obtained from the New York Blood Center
(New York, NY). The PBMC were cultured in lymphocyte
medium (LM) [RPMI 1640 supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine (all media from
Cellgro, Herndon, VA), and 100 U/ml IL-2 (NIH AIDS Re-
search and Reference Reagent Program, contributed by Hoff-
man-LaRoche, Inc.)]. Equal parts of each PBMC culture were
stimulated with either 5 μg/ml phytohemagglutinin (PHA;
Sigma, St. Louis, MO) or with supernatant from the OKT3
hybridoma (anti-CD3 stimulation). After 3 days, an equal
number of cells from the two different stimulation cultures were
combined. PHA and OKT3 were removed by washing. Titration
medium (TM, which is LM containing 100 μg/ml penicillin/
streptomycin) was added for the remainder of the culture period
(Ketas et al., 2003b). The PBMC were seeded at 100 μl per well
into a 96-well plate (Becton Dickinson) at 1.4×106 cells/ml in
TM before addition of a serially diluted inhibitor immediately
prior to inoculation of the test virus (100 TCID50/well). The
cultures were then continued with both virus and inhibitors
present. HIV-1 replication was measured using an in-house p24
antigen ELISA on Day 7, then again on Day 10 or 14 if viral
replication was insufficient. Residual p24 from the input virus
was measured and subtracted in order to calculate total net p24
production (intracellular and extracellular) in the test wells.Inhibition was expressed relative to p24 production in the
control wells (no inhibitor, defined as 0% inhibition).
Statistical and mathematical analysis
The effect of the various inhibitors on the replication of a
panel of HIV-1 test isolates in PBMC is presented in two
different ways: (1) as the relative frequency of inhibition above
a defined cut-off value; and (2) as the average degree of
inhibition.
In the first method, the cut-off value for calculating the
frequency of inhibition was selected to be 90% reduction of p24
production compared with control cultures (i.e., no inhibitor
present). The rationale for this cut-off is that a 90% reduction in
the infectivity of the inocula commonly used for experimental
transmission of challenge viruses to macaques should provide
significant protection from infection (Klasse et al., 2006).
Within each virus test panel, the number of isolates inhibited by
>90% is divided by the total number of isolates in the panel; the
resulting relative frequency is presented as a percentage. The
rationale here is that frequencies based on a high cut-off are
likely to be the most important from the perspective of the
practical development of an intervention strategy such as a
microbicide. In other words, what proportion of the divergent
viruses an inhibitor might encounter when used as a microbicide
could it be expected to be effective against?
Because the above method of data presentation obscures any
differences in partial inhibition that occur below the cut-off
value (i.e., from 0 to 90% inhibition of p24 production), we also
calculated the average degree of inhibition (±standard devia-
tion) for all the isolates in each test panel. This strategy provides
a complementary means of gauging the increase in inhibition
resulting from combining two or more inhibitors. Biologically,
this is relevant to the question: When the concentrations of
individual inhibitors at mucosal sites fall below what is required
for protection (e.g. in mucosal microenvironments, and over
time), will their use in combinations still be able to counter the
infectious inoculum?
In addition, to assess whether any test isolates were pan-
resistant to all the relevant inhibitors (as opposed to being
resistant to individual ones), we performed pair-wise correla-
tions of the degree of inhibition by fixed concentrations of each
inhibitor. Finally, to address whether variation in the extent to
which different test isolates replicated caused the extent of
inhibition by a test compound also to vary, we correlated the
extent of inhibition with the amount of p24 produced in the
absence of an inhibitor. These correlations were performed and
the r2 values were calculated using Prism (GraphPad). The
justification for performing this analysis by correlations, rather
than linear regression, is that only experimental variables, and
no controlled parameters, were plotted against each other.
We addressed whether there was any genetic subtype-specific
effect of the various inhibitors (alone and combined) by
comparing the degrees of inhibition at fixed, intermediate
concentrations, in a Kruskal–Wallis one-way analysis of
variance by ranks. This non-parametric test was chosen because
the sample numbers were sometimes too small to evaluate
439T.J. Ketas et al. / Virology 364 (2007) 431–440Gaussian distributions. When the Kruskal–Wallis test indicated
that there were no overall discrepancies in rank sums among the
groups (p>0.05), Dunn's post-test was not done. All statistical
analyses were performed in Prism (GraphPad).
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